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Background and purpose: The persistent influx of neutrophils into the lung and subsequent tissue damage are
characteristics of COPD, cystic fibrosis and acute lung inflammation. VAP-1/SSAO is an endothelial bound adhesion
molecule with amine oxidase activity that is reported to be involved in neutrophil egress from the microvasculature
during inflammation. This study explored the role of VAP-1/SSAO in neutrophilic lung mediated diseases and
examined the therapeutic potential of the selective inhibitor PXS-4728A.
Methods: Mice treated with PXS-4728A underwent intra-vital microscopy visualization of the cremaster muscle
upon CXCL1/KC stimulation. LPS inflammation, Klebsiella pneumoniae infection, cecal ligation and puncture as well
as rhinovirus exacerbated asthma models were also assessed using PXS-4728A.
Results: Selective VAP-1/SSAO inhibition by PXS-4728A diminished leukocyte rolling and adherence induced by
CXCL1/KC. Inhibition of VAP-1/SSAO also dampened the migration of neutrophils to the lungs in response to LPS,
Klebsiella pneumoniae lung infection and CLP induced sepsis; whilst still allowing for normal neutrophil defense
function, resulting in increased survival. The functional effects of this inhibition were demonstrated in the RV
exacerbated asthma model, with a reduction in cellular infiltrate correlating with a reduction in airways hyperractivity.
Conclusions and implications: This study demonstrates that the endothelial cell ligand VAP-1/SSAO contributes to the
migration of neutrophils during acute lung inflammation, pulmonary infection and airway hyperractivity. These results
highlight the potential of inhibiting of VAP-1/SSAO enzymatic function, by PXS-4728A, as a novel therapeutic approach
in lung diseases that are characterized by neutrophilic pattern of inflammation.
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Several inflammatory diseases of the lung including chronic
obstructive pulmonary disease (COPD), cystic fibrosis (CF),
acute lung injury and bronchiolitis obliterans syndrome are
predominantly characterized by neutrophilic infiltration
[1-4]. Neutrophils are polymorphonuclear phagocytic gran-
ulocytes and during normal immune responses act as the
first line of defense against microorganisms by finding and
neutralizing bacteria and fungi [5]. Excessive neutrophilia* Correspondence: Heidi.Schilter@pharmaxis.com.au
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unless otherwise stated.coupled with inadequate removal of neutrophils (and their
byproducts) results in the subsequent and persistent release
of a number of inflammatory mediators and proteinases
that contribute to progressive fibrosis and destruction of
the lung parenchyma [6-8].
Integral to the proper functioning of neutrophils in lung
defense is their ability to egress from the microvasculature
and migrate through tissues to the targeted site. Upon injury
of organs, neutrophils up-regulate expression of cell surface
receptors (such as CD44 and CD11b) [9,10]; these subse-
quently bind to adhesion molecules on endothelial cells
(E-selectin, P-selectin, VAP-1/SSAO, ICAM-1), enabling
neutrophil transmigration through the endothelial cell lining
into the underlying parenchyma [5,11]. In the pulmonary. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Structure of PXS-4728A.
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occurs from the capillaries, and so far only neutrophil rolling
and deformability (not adhesion) have been implicated in
this process [12-16].
Given the potential of targeting neutrophil migration via
their adhesion process, a number of small molecules have
now been developed against neutrophil inflammation. Tar-
geting P-selectin glycoprotein ligand 1 (PSGL-1/CD162)
and Mac-1 (CD11b/CD18), not only inhibits pulmonary
recruitment of neutrophils but also reduces lung damage
in sepsis (29, 30). Neutralization of CD44 reduced cecal
ligation puncture (CLP) induced pulmonary accumulation
of neutrophils. Studies have also shown that neutrophilic
inflammation induced by lipopolysaccharides (LPS) is at-
tenuated in CXCR2 deficient mice and small molecule
CXCR2 antagonists inhibit pulmonary neutrophilic inflam-
mation induced by inhaled LPS [17,18]. Administration of
the CXCR2 antagonists SCH527123 and SB-656933 has
been shown to inhibit the increased neutrophil content in
sputum as a result of ozone challenge in normal volun-
teers, while AZD8309 also was shown to be efficacious
during inhaled LPS challenge in normal volunteers [19-21].
Another potential target for impacting neutrophil inflam-
mation is to inhibit their migration via the adhesion mol-
ecule VAP-1/SSAO. VAP-1 is a homodimeric 170-kDa
sialoglycoprotein that regulates adhesion and consequently
transendothelial migration of leukocytes [22]. It is unique
amongst the adhesion molecules as it also functions as a
semicarbazide-sensitive amine oxidase (SSAO), which is
part of a family of amine oxidases capable of oxidizing pri-
mary amines (e.g. methylamine) to the corresponding alde-
hyde (e.g. formaldehyde), releasing hydrogen peroxide and
ammonia. It is highly expressed on the endothelium of the
lungs and trachea, whereas absent from leukocytes and
epithelial cells [23]. Although the exact function of SSAO
in the lung is not well elucidated, it has been suggested that
SSAO might be involved in the recruitment of inflamma-
tory cells during pulmonary inflammation [23-25].
VAP-1/SSAO overexpressing transgenic animals show
higher baseline cell counts in the BALF (bronchoalveolar
lavage fluid) than in non-transgenic mice, indicative of in-
creased lung inflammation, due to increased VAP-1/SSAO
levels [25]. The pro-inflammatory effect of VAP-1/SSAO
was evident when transgenic mice were stimulated with
LPS; inflammation was significantly higher in the trans-
genic than in the non-transgenic mice [25]. Neutrophil
migration through the endothelium was shown to be
dependent on both the adhesive and the enzymatic func-
tions, with mAb and small molecule enzyme inhibitors
reducing the influx of neutrophils. However, these effects
were not additive, indicative of a common downstream
process [22,24].
The present study demonstrates for the first time in vivo,
that inhibition of the enzymatic function of VAP-1/SSAOby a small molecule impairs neutrophil migration by medi-
ating tethering and rolling onto the vascular endothelium.
Using the small molecule inhibitor PXS-4728A, a crucial
role for the enzymatic function of VAP-1/SSAO was iden-
tified in the pathogenesis of neutrophil lung inflammation,
injury and airway hyperreactivity. This article provides
support that targeting VAP-1/SSAO is a potential strategy
to inhibit the underlying neutrophil inflammation that con-




PXS-4728A (Figure 1) is a low molecular weight fluoro-
allylamine and chemically similar to the previously
described VAP-1/SSAO inhibitor PXS-4681A [24].
SSAO fluorometric enzyme activity assay
Enzymatic activity measurement was based on the produc-
tion of H2O2 as described previously [24]. When measur-
ing activity from tissue, samples were incubated with
0.5 mM of pargyline, to inhibit any potential endogenous
monoamine oxidase A and B. In a 384 well plate (Greiner
384 Well Black Microclear Base), 25 μl of the samples were
incubated for 30 min at 37°C with or without the specific
SSAO inhibitor (1 μM Mofegiline). A reaction mixture
containing amplex red (120 μM; Life Technologies,
Australia, A12222), horseradish peroxidase (1.5 U/ml;
Sigma-Aldrich; P2088-5KU) and Benzylamine (600 μM for
rhSSAO; 80 μM for mouse tissue, 30 μM for rat tissue)
was prepared in 0.1 M sodium phosphate buffer. 25 μl of
the reaction mixture were added into each well after the
30 min incubation. The relative fluorescence units (RFU)
were read every 2.5 min for 30 min at 37°C, excitation
565 nm and emission 590 (Optima, BMG labtech), and the
slope of the kinetic curves for each sample was calculated
using MARS data analysis software (BMG labtech) as in
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in the presence of the specific SSAO inhibitor (1 μM
Mofegiline low signal control) and in the absence of the in-
hibitor (high signal control) was considered to be the spe-
cific SSAO activity in the sample. For animal tissues, the
signal obtained from the non-treated group was considered
to be 100% and all other groups were adjusted accordingly
to yield a % response graph. IC50 values were calculated
from the concentration-response curves using Studies
software (Dotmatics, UK).
Purified recombinant human VAP-1/SSAO (rhSSAO)
was obtained from CSIRO (Australia).
Other fluorometric enzyme activity assays
MAO-A, MAO-B, DAO, LOXL2 and LOX enzymatic
assays followed the same protocol as for SSAO, with
slight modifications.
For recombinant human monoamine oxidases A and B
(rhMAO-A and rhMAO-B, Sigma-Aldrich) the following
substrates were used: 200 μM tyramine (Sigma-Aldrich)
for rhMAO-A, and 100 μM benzylamine for rhMAO-B.
The low controls for rhMAO-A and rhMAO-B assay
were 1.5 μM clorgiline (Sigma-Aldrich) and 1 μM mofe-
giline, respectively.
Recombinant human diamine oxidase (rhDAO, kindly
provided by Prof. Mitchell Guss, University of Sydney,
Australia), inhibition assay utilized 200 μM putrescine and
10 μM of inhibitor aminoguanidine (both from Sigma-
Aldrich) as substrate and low control, respectively.
rhLOXL2 (lysyl oxidase like 2) was purchased from R&D
systems and assay was performed in 1.2 M urea, 50 mM
sodium borate buffer, pH 8.2. The substrate used was
10 mM putrescine and 100 μM of β-aminopropionitrile
(βAPN, Sigma-Aldrich) was added to the low controls.
Bovine Lysyl Oxidase (LOX) was extracted by adapting
the methodology from Rucker et al. [26] from calf aorta:
the homogenized tissue was washed extensively from
readily soluble proteins and salts with PBS, and then
extracted in 4 M urea, 50 mM sodium borate buffer,
pH 8.2. The supernatant underwent buffer exchange
and was concentrated by means of Amicon 10 kDa centri-
fuge filters (Millipore) in 1.2 M urea, 50 mM sodium borate
buffer, pH 8.2 and in the presence of protease inhibitors
(0.5 mM phenylmethylsulfonyl fluoride, 0.5 mM N-
ethlylmaleimide, 0.5 mM p-aminobenzoic acid, 20 mg/
mL soybean trypsin inhibitor, all from Sigma-Aldrich).
LOX enzyme mixture was pre-treated with 0.5 mM pargy-
line and 1 μM mofegiline (to inhibit any potential en-
dogenous monoamine oxidase A and B as well as SSAO),
in 1.2 M Urea buffer, 50 mM sodium borate, pH 8.2. The
substrate used was 10 mM putrescine and 100 μM of
β-aminopropionitrile (βAPN, Sigma-Aldrich) was added
to the low control. Reaction mix was made up in 1.2 M
urea, 50 mM sodium borate buffer, pH 8.2.Off-target activity
PXS-4728A, was tested at Ricerca Inc in the “lead seeker
selectivity panel”, which tests over 100 different targets.
Pharmacokinetics and pharmacodynamics
Studies were performed by ICP Firefly, Pharmalegacy and
Sundia with local ethics approval. Wistar rats were admin-
istered PXS-4728A orally at 6 mg.kg−1 or intravenously at
3 mg.kg−1, while BALB/c mice received PXS-4728A orally
at 10 mg.kg−1 or intravenously at 5 mg.kg−1. Plasma was
analyzed for PXS-4728A by high-performance liquid
chromatography-mass spectrometry/mass spectrometry.
Basic pharmacokinetic parameters were estimated using
PK Solutions software (Summit Research Services).
To measure SSAO activity, animals were euthanized
after 24 hours and abdominal fat as well as lung was
collected. Tissue samples were surgically removed and
weighed, homogenized in ice-cold HES buffer (20 mM
HEPES, 1 mM EDTA, Sucrose 250 mM, 1× proteases and
phosphatases inhibitor, pH 7.4) at a final concentration of
1 g/20 mL (mouse fat), 1 g/5 ml (rat lung and fat). The
homogenate underwent 2000 rpm centrifugation for 5 min
at 4°C and the supernatant was diluted in assay buffer
(0.1 M sodium phosphate buffer), 1:20 (rat tissues) or 1:5
(mouse tissues). Supernatant was analysed using the
fluorometric method for SSAO activity as described above.
Induction of cremaster inflammation
Study was performed following UFMG (Federal University
of Minas Gerais) local ethics committee approval. BALB/c
mice were anesthetized and 500 ng of murine rCXCL1 in
0.2 ml of saline was administered locally by s.c. injection
beneath the right scrotal skin using a 30-G needle, 2 hours
before exteriorization. The left cremaster was then pre-
pared for intravital microscopy, as previously described
[27]. Briefly, an incision was made in the scrotal skin to
expose the left cremaster muscle, which was then carefully
removed from the associated fascia. A lengthwise incision
was made on the ventral surface of the cremaster muscle
using a cautery. The testicle and the epididymis were sepa-
rated from the underlying muscle and were moved into the
abdominal cavity. The muscle was then spread out over an
optically clear viewing pedestal and was secured along the
edges with a 4–0 suture. The exposed tissue was super-
fused with warm bicarbonate-buffered saline (pH 7.4). An
intravital microscope (Olympus BX50F4) with a 20× ob-
jective lens and a 10× eyepiece was used to examine the
cremasteric microcirculation. A video camera (CDD; Sony)
was used to project the images onto a monitor, and the
images were recorded for playback analysis using a con-
ventional DVD. Single, unbranched cremasteric venules
(25–40 μm in diameter) were selected and, to minimize
variability, the same section of cremasteric venule was
observed throughout the experiment. The number of
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during video playback analysis. Rolling leukocytes were
defined as those cells moving at a velocity less than that
of erythrocytes within a given vessel. The flux of rolling
cells was measured as the number of rolling cells passing
by a given point in the venule per minute. A leukocyte
was considered to be adherent if it remained stationary for
at least 30 s, and total leukocyte adhesion was quantified
as the number of adherent cells within a 100 μm length of
venule. PXS-4728A (6 mg.kg−1) was given orally 1 hour
prior to 500 ng of murine rCXCL1.
Lipopolysaccharide (LPS) airway inflammation
6 hour time point: the study was performed by Washington
Biotechnology with approval from local ethics committee.
BALB/c animals were anesthetized, a midline incision
was made in the neck, the muscle layers separated by
blunt dissection, and 6 μg/LPS from E. coli strain
055:B5 injected into the trachea. The incision was
closed with wound clips and the mice returned to cages.
PXS-4728A (0.2 or 2 mg.kg−1) or dexamethasone
(10 mg.kg−1) was given orally 1 hour prior to stimulus sur-
gery. Dose of dexamethasone was chosen based on the in-
hibitory results depicted in the literature [28].
24 hour time point: the study was performed by Phar-
malegacy with approval from local ethics committee. Swiss
mice were anesthetized and 500 μg of LPS from E. coli
strain 0111:B4 was intranasally instilled.PXS-4728A
(4 mg.kg−1) or dexamethasone (10 mg.kg−1) was given
orally 1 hour prior to stimulus. PXS-4728A (6 mg.kg−1) was
administered a second time 6 hours post stimulus. Given
the short half-life of PXS-4728, a second dose was admin-
istered to ensure that newly synthesized SSAO would also
be blocked.
At 6 hours or 24 hours, mice were euthanized and bron-
choalveolar lavage (BAL) was performed for recovery of
airway luminal cells. Briefly, lungs were gently lavaged via
tracheal cannula with 0.5 mL of PBS. The procedure was
repeated twice with 0.5 mL PBS. BAL was centrifuged at
4°C with 300 g × 5 min and cells were suspended by
0.3 mL PBS. Total cell number and differential cell counts
in BALF by haemocytometer. Differential cell counts (lym-
phocytes, eosinophils, macrophages and neutrophils) were
made from cytocentrifuged preparations using cytospins
and after staining with Wright-Giemsa.
Klebsiella infection
Study was performed at the Pre-Clinical Services group at
the University of North Texas Health Science Center with
approval from local ethics committee. BALB/c mice were
anesthetized and inoculated intranasally with 105 – 107 CFU
of Klebsiella pneumoniae (UNT024-1 ATCC43816).
At 24 hours BAL was collected as described for the LPS
model, following the BAL, lungs were homogenized insterile PBS using a Polytron tissue homogenizer, serially
diluted (8 × 10-fold dilutions) and all dilutions plated on
Trypticase soy agar + charcoal (to prevent the effects any
compound carryover) for the determination of tissue asso-
ciated bacterial CFU counts. PXS-4728A (6 mg.kg−1) or
dexamethasone (10 mg.kg−1) was given orally 1 hour prior
to infection. For survival analysis, animals were treated
1 hour prior to infection and daily thereafter. To maintain
consistency in dexamethasone treatment between models,
a 10 mg.kg−1 dose was utilized.
Induction of the cecal ligation and puncture insult
Study was performed following UFMG (Federal University of
Minas Gerais) local ethics committee approval. The CLP
procedure involved a laparotomy and ligation of the cecum,
distal to the ileo-cecal valve. C57/BL6 mice were anesthetized
and the cecum was punctured, with a 21-gauge needle to
induce moderate sepsis, following the needle a small
amount of fecal matter was extruded from each puncture.
Following ligation and puncture, the cecum was returned to
the abdomen, the peritoneal wall and skin incisions were
closed, and the animals were allowed to recover. Sham
animals received a laparotomy without manipulation of the
cecum. Animals were euthanized after 6 hours following in-
duction of sepsis and BAL as well as peritoneal cavity wash
(with 1.5 ml of PBS containing 1 mM EDTA) was performed
for analysis of total and differential cell counts. Lungs were
removed for myeloperoxidase activity measurement as previ-
ously described [29]. Briefly, before lung removal, the pul-
monary vasculature was perfused with 3 ml of PBS through
the right ventricle, and the organ was removed and frozen.
Upon thawing, the right lobe (0.1 g of tissue per 1.9 ml of
buffer) was homogenized in a pH 4.7 buffer (0.1 M NaCl,
0.02 M Na2PO4, 0.015 M Na2EDTA), centrifuged at 3000 g
for 10 minutes, and the pellet subjected to hypotonic lysis
(1.5 ml of 0.2% NaCl solution) followed by an addition 30 sec-
onds later of an equal volume of a solution containing NaCl
1.6% and glucose 5%. After a further centrifugation, the pellet
was resuspended in 0.05 M Na2PO4 buffer (pH 5.4) contain-
ing 0.5% hexadecyl-trimethylammonium bromide (HTAB)
and re-homogenized. One-milliliter aliquots of the suspen-
sion were transferred into 1.5-ml micro- tubes followed by
three freeze-thaw cycles using liquid nitrogen. The aliquots
were then centrifuged for 15 minutes at 3000 g to perform
the assay. PXS-4728A (6 mg.kg−1) or dexamethasone
(5 mg.kg−1) was given orally 1 hour prior to surgery. For
survival animals were treated 1 hour prior to infection and
daily thereafter. Dose for dexamethasone was chosen based
on previously observed findings (unpublished results).
House dust mite/Rhinovirus model
Study performed at the University of Newcastle under
local ethics committee. BALB/c mice were sensitized and
challenged intranasally to 50 μg of crude HDM extract
Table 1 Activity and selectivity of PXS-4728A in vitro
Assay IC50
Recombinant human VAP-1/SSAO (AOC3) 5 nM




Recombinant diamine oxidase (AOC1) 12.0 μM >2000x
Recombinant retina specific amine oxidase
(AOC2)
2.76 μM >500x
Purified lysyl oxidase from lung fibroblasts 13.2 μM >2000x
Recombinant lysyl oxidase like 2 10.4 μM >2000x
Recombinant monoamine oxidase A >100 μM >2000x
Recombinant monoamine oxidase B 2.7 μM >500x
Recombinant lysine demethylase >10 μM >2000x
Table 2 Pharmacokinetic profile of PXS-4728A in rodents
Rat Mouse
Oral dose 6 mg.kg−1 10 mg.kg−1
Bioavailability (%) 55 92
Apparent concentration at curve maximum
Cmax (μg.ml−1)
0.72 1.38
Time of maximal concentration Tmax (hour) 0.83 0.25
Clearance CL (ml.kg.min−1) 45 98
Intravenous dose 3 mg.kg−1 5 mg.kg−1
Apparent concentration at curve maximum
Cmax (μg.ml−1)
4.21 1.6
Time of maximal concentration Tmax (min) 0.03 0.03
Clearance CL (ml.kg.min−1) 23 80
Apparent half-life, t1/2 (h) 1.1 0.6
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from Greer Laboratories) on days 0, 1 and 2 followed by
four exposures of 5 μg HDM daily from day 14 to day 17
delivered in 50 μl of sterile saline. Animals were then
infected on day 18 with infective Human Rhinovirus 1b
RV1B41 (2.5 × 106 median tissue culture infective dose)
intranasally [30]. Mice were intranasally administered
50 μl infective or ultraviolet light (UV)–inactivated
RV1B41. Mice were euthanized 24 hours after the rhino-
virus challenge. BAL analysis was performed for total and
differential counts and airway hyperreactivity (AHR) was
assessed invasively by measurement of total lung resist-
ance and dynamic compliance (BUXCO) in response to
methacholine challenge as previously described [31]. PXS-
4728A (2 mg.kg−1), dexamethasone (2 mg.kg−1), azithro-
mycin (25 mg.kg−1) or saline was delivered (ip.), post final
intransal HDM challenge and prior to intranasal Rhino-
virus inoculation. Dose of azithromycin was chosen based
on previously described findings, in respiratory viral infec-
tion models [32].
Survival analysis
Experiments complied with stringent ethics protocols from
UNTHSC (for the Klebisella model) or UFMG (for the
CLP model). An important aspect of the ethics regulations
was that pain and distress be minimized whenever possible.
Therefore, experiments were performed as to avoid animal
discomfort, unless necessary to achieve the goals of the
study. Animals were closely monitored and if animals
reached >20% weight loss or were in moribund state they
were euthanized. Once animals started to display clinical
signs of illness, investigators monitored the subjects more
frequently to ensure timely identification of moribund
animals. Investigators were obligated to make every effort
to identify and humanely euthanize moribund animals that
had not responded to treatment.
Statistical analysis
Statistical analysis was performed by one-way ANOVA with
Newman-Keuls Multiple Comparison Test, unless other-
wise stated. Data are represented as Mean with S.E.M.
Results
PXS-4728A compound profile
PXS-4728A exhibited an IC50 of <10 nM against the human
VAP-1/SSAO enzyme and this activity was maintained
across all the mammalian species tested (Table 1). The com-
pound was found to be more than 500-fold selective for
VAP-1/SSAO over all the related human amine oxidases.
PXS-4728A shares the excellent potency, selectivity (as seen
in Table 1) and oral bioavailability (Table 2) with the previ-
ously described compound PXS-4681A [24] but has a more
balanced blood/plasma ratio (1.2 for human and dog, 1.45
for rat) due to substitution of the sulfonamide group withan amide, removing all activity for carbonic anhydrase II
and thereby avoiding the potential for sequestration by
erythrocytes in whole blood. Like PXS-4681A, PXS-
4728A is stable in human, rat and dog plasma (>90%
remaining after 1 hour incubation) and has high water
solubility >10 mg.ml−1 at pH 7.4. PXS-4728A is a
mechanism-based inhibitor of VAP-1/SSAO with Ki of
175 nM and Kinact of 0.68 min−1 when determined by
time-dependent inhibition using Kitz-Wilson plot.Pharmacokinetic parameters
The pharmacokinetic (PK) properties of PXS-4728A were
investigated in rats and mice (n = 3 in each group) and are
reported in Table 2. In rats when dosed at 6/3 mg.kg−1
(oral/i.v.), PXS-4728A presented a bioavailability of >55%
and a half-life of approximately 1 hour (i.v.). As the models
of inflammation in this study were performed in mice, the
PK profile of PXS-4728A was also evaluated in BALB/c
mice (Table 2). Mice were dosed at 10/5 mg.kg−1 (oral/i.v.)
and PXS-4728A presented a high bioavailability of >90%, a
maximal concentration of 1.38 μg.ml−1 was reached and all
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data.
PXS-4728A does not have any significant off-target
activity when tested against other amine oxidases or over
100 different macromolecular targets. PXS-4728A does
not induce cell toxicity or phospholipidosis in HepG2
cells (highest concentration tested 100 μM).Pharmacodynamic (PD) profile
To determine the inhibition of SSAO by PXS-4728A, ab-
dominal adipose tissue was collected at 24 hours after dos-
ing. The adipose tissue was chosen as it had been previously
described to contain high quantities of SSAO, allowing a
large assay window to detect enzyme inhibition [33].
Mice administered orally with a single dose of 0.2 and
0.6 mg.kg−1 showed a 60-70% reduction in SSAO activity
compared to the control group (slope of ~153 in a 1%
tissue/buffer solution) at 24 hours, whilst 2 mg.kg−1 dosing
resulted in over 80% inhibition of the enzyme (Figure 2A).
Due to the focus of the present study on respiratory disease
models, activity of the enzyme was then tested in the
mouse lung; however this procedure was unsuccessful
as the AR/HRP assay available did not provide enough
sensitivity. To overcome this, the pharmacodynamic profile
was analyzed in the rat.
Rats administered with an oral dose of 0.2 mg.kg−1
showed a 55% reduction in SSAO activity in the adipose
tissue compared to the control group (slope of ~116 in a
1% tissue/buffer solution), whilst 0.6 and 2 mg.kg−1 dosing
resulted in over 80% inhibition of the enzyme (Figure 2B).
SSAO activity in the lungs of rats showed that 0.6 and
2 mg.kg−1 resulted in near-total inhibition of the enzyme
at 24 hours (Figure 2C) compared to the control group
(slope of ~138 in a 1% tissue/buffer solution).
Given the comparable PD results in the adipose tissue
between the mouse and rat it was presumed that the PDFigure 2 Pharmacodynamic profile of PXS-4728A 24 hours after dosin
untreated control; (A) single time point with escalating doses in the (A) ad
of Wistar rats.in the lung would be similar (SSAO enzyme should be
inhibited).
The results from mouse PK and PD indicate that doses
of 2 mg.kg−1 or greater were needed to achieve maximal
inhibition of SSAO function. Since the anti-inflammatory
effects are seen only when complete inhibition of the
enzyme activity is achieved [24] the models described in
this study are focused on doses of ≥ 2 mg.kg−1.
Inhibition of cell adhesion and rolling
At the cellular level VAP-1/SSAO knockout animals have
increased leukocyte velocity, causing decreased adhesion in
the cremaster model [34]. However, the direct effects of
VAP-1/SSAO small molecule inhibitors on neutrophil
egress from the microvasculature in vivo have not been de-
termined. The mouse cremaster model allows visualization
of the early steps of PMN (polymorphonuclear leukocyte)
migration. After exposure of the cremaster muscle, cell re-
cruitment was induced by cytokine injection and analyzed
by an intravital microscopy. CXCL1/KC caused PMN to
tether and strongly adhere to endothelia cells and subse-
quently migrate. Transendothelial migration is difficult to
measure in a two dimensional space therefore the quantita-
tive analysis was restricted to rolling and adhering leuko-
cytes (Figure 3). CXCL1/KC increased the number of
rolling and adhering leukocytes and this was abolished by a
6 mg.kg−1 oral dose of PXS-4728A (Figure 3A/B). These
data demonstrate that the enzymatic activity of VAP-1/
SSAO is required in the initial steps of neutrophil migra-
tion and inhibition of VAP-1/SSAO could potentially pre-
vent the events that lead to the migration of leukocytes to
the site of inflammation.
VAP-1/SSAO inhibition of neutrophil migration
To demonstrate that inhibition of leukocyte rolling and
adhering by PXS-4728A translates into a reduction in
inflammation; a model of neutrophilic acute lung injuryg. Measurement of total VAP-1/SSAO activity (%) compared to
ipose tissue of BALB/c mice (B) adipose tissue of Wistar rats (C) lung
Figure 3 Inhibition of cell adhesion and rolling by PXS-4728A. Inhibition of VAP-1/SSAO dampened the (A) rolling and (B) adhesion of
leukocytes after CXCL1 stimulation. N = 5-6 per group; **p < 0.01 over vehicle.
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is a component of the cell wall of Gram-negative bac-
teria and is a well-established stimulant of neutrophilic
inflammation. Animals were exposed to LPS and neutro-
phil recruitment into the lungs was monitored at differ-
ent time points. As expected, LPS increased the number
of airway neutrophils in bronchoalveolar lavage fluid
(BALF) at 6 hours (Figure 4A/B) in BALB/c mice. Neu-
trophil inflammation was highly dependent on VAP-1/
SSAO enzymatic function, as PXS-4728A dampened
migration significantly and comparable of the reduction
by dexamethasone.
To strengthen this finding a different mouse strain,
SWISS, at the 24 hour time time point was used. At
twenty-four hours post LPS stimulation, airway inflam-
mation was present as can be seen by the increase in
total cell counts and neutrophils (Figure 4C/D). PXS-
4728A applied 1 hour before and 6 hours after the insult
still reduced inflammation. This demonstrates that inde-
pendent of the mouse strain PXS-4728A can diminish
inflammation during early and late responses.
It is plausible that limiting neutrophil migration into
the airway spaces could lead to a build-up of cells in
the blood vessels and therefore blood counts were
performed. There was an increase in neutrophils in the
circulation upon LPS stimulus and this increase was
unaffected upon VAP-1/SSAO inhibition (Figure 5A/B).
These results confirm that reducing emigration of cells
from the blood vessel (via VAP-1/SSAO) has no effect
on the accumulation of blood circulating neutrophils.
Bacterial infections are often the underlying cause of
chronic lung inflammation, to further investigate the
potential beneficial effects of SSAO/VAP-1 inhibition in
lung inflammation, animals underwent a bacterial infection
model. Animals were infected with Klebsiella pneumoniae
as this is a frequently occurring Gram-negative bacteria
with high replicating properties. Animals inoculated intra-
nasally with Klebsiella pneumoniae showed an increase inairway leukocytes, particularly neutrophils (Figure 6A/B).
Upon inhibition of VAP-1/SSAO, the migration of these
cells to the site of infection was significantly dampened,
similar to the effects of dexamethasone. It is important
to note that although VAP-1/SSAO inhibition lead to an
increase in bacterial compared to the vehicle control
(Figure 6C), this did not reach a log unit difference [vehicle
(7.59 LOG 10-CFU) and PXS-4728A (8.27 LOG 10-CFU)],
this is of particular importance as bacteria replicate
exponentially, in addition the survival of animals was not
compromised (Figure 6D). It is noteworthy that when in-
flammation was ablated by the use of glucocorticosteroids,
the difference in survival was significant between the two
treatment groups. This demonstrates that inhibition of cell
adhesion/rolling via VAP-1/SSAO reduces rather than
abolishes neutrophil infiltration, allowing a sufficient
neutrophilic response with which to combat an infection.
The results described above show that after a localised
stimulus by LPS and Klebsiella pneumoniae infection,
neutrophil extravasation into the airways was VAP-1/
SSAO dependent. To further expand the role of SSAO/
VAP-1 in respiratory inflammation, neutrophil migration
during a generalized systemic infection was studied. Sep-
sis is a condition characterized by dysregulated systemic
inflammatory response. Sepsis induced by cecal ligation
and puncture (CLP) is the most frequently used model
as it has the advantage of closely resembling the progres-
sion and characteristics of human sepsis [35]. CLP is
triggered by a polymicrobial infection, which begins as
peritonitis and is followed by a systemic inflammatory
response with a destructive lung inflammatory compo-
nent (acute lung injury). As such, this model has a very
robust neutrophilic element in the peritoneal and lung
compartments as well as an aggressive systemic bacterial
infection. The CLP model was performed in mice pre-
treated with the VAP-1/SSAO inhibitor. The proportion
of total peritoneal inflammatory cells as well as periton-
eal neutrophils at 6 hours (Figure 7A/B) was not affected
Figure 4 Inhibition of LPS induced inflammation. LPS caused an increase in total number of cells and neutrophils in the BALF, as
measured 6 and 24 hours after the insult. Pre-treatment with PXS-4728A (VAP-1/SSAO inhibitor) concentration-dependently reduced the influx of
(A) total cells and (B) neutrophils at 6 hours. Pre-treatment with 4 mg/kg of PXS-4728A (VAP-1/SSAO inhibitor), followed by a repeat treatment
of 6 mg/kg at 6 hours reduced the influx of (C) total cells and (D) neutrophils. N = 6-12 per group; *p < 0.05, **p < 0.01, ***p < 0.001 over vehicle.
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by dexamethasone indicating that the defense system
during a severe infection is not compromised.
Interestingly, VAP-1/SSAO inhibition significantly damp-
ened the lung injury induced by CLP, with a reduction in
total cells, neutrophils, as well as myeloperoxidase in the
lung (Figure 7C-E). Although it did not reach significance,
survival benefits were evident after VAP-1/SSAO inhibition
(Figure 7F), as PXS-4728A administration increased survivalFigure 5 Circulating leukocytes during LPS induced inflammation. LPS
24 hours after the insult. Pre-treatment with PXS-4728A (VAP-1/SSAO inhib
in the non LPS group, N = 12 in the LPS treated groups.rates compared with control animals from 50% to 90%
(p = 0.057). These results show that VAP-1/SSAO has dis-
tinct roles in different tissues, with inhibition of inflamma-
tion in the lung, yet no effect on leukocytes in the peritoneal
cavity during very severe infection. This highlights a benefi-
cial effect of inhibition of VAP-1/SSAO as it is able to re-
duce lung injury but does not reduce systemic host defence.
Having established that selective VAP-1/SSAO inhibition
alters the migration of neutrophils in response to acutecaused increased neutrophilia in the blood vessel as measured
itor) had no effect on (A) total cells or (B) circulating neutrophils. N = 8
Figure 6 Inhibition of inflammation during Klebsiella pneumonia infection. Mice were inoculated intranasally with 0.05 mL of ~105 – 107
input CFU of Klebsiella pneumoniae. Inhibition of VAP-1/SSAO dampened (A) total leukocyte as well as (B) neutrophil migration into the airway
spaces and increased bacterial load (C). (D) Although bacterial counts were higher in the VAP-1/SSAO inhibited group, survival was not affected;-
comparison in the survival of dexamethasone treated animals to PXS-4728A was of p < 0.0018. N = 8 per group for the BALF and bacterial counts,
N = 10 for survival; **p < 0.01, ***p < 0.001 over vehicle.
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allowing normal neutrophil defense; the role of VAP-1/
SSAO during a viral infection was assessed. Rhinovirus
infection was performed concomitant with the house dust
mite asthma model in order to mimic a viral exacerbated
asthmatic response. Rhinoviruses (RV) have been identified
as being the main perpetrators of asthma exacerbations,
which is characterized by increases in airway hyperreactiv-
ity and neutrophilia [31]. Inhibiting VAP-1/SSAO prior to
the viral infection significantly dampened the neutrophil
infiltrate in a manner comparable to that of the macrolide
azithromycin (Figure 8A). In this model azithromycin - a
macrolide which shows great promise in the clinic for the
treatment of asthma- was used as a comparator as dexa-
methasone has no impact on RV1b induced neutrophilic
inflammation of the HDM allergic lungs. The reduced cel-
lular infiltrate following VAP-1/SSAO inhibition correlated
with a significant reduction to the exacerbation of airways
hyperreactivity (AHR) in response to methacholine chal-
lenge (Figure 8B).Discussion
These studies clearly show that inhibition of the enzym-
atic activity of VAP-1/SSAO by PXS-4728A diminishes
lung inflammation in a variety of models suggesting that
this mechanism plays an important role in respiratory
diseases. PXS-4728A is a highly selective inhibitor of
VAP-1/SSAO, with exquisite pharmacodynamic and
pharmacokinetic properties, that inhibits neutrophil
rolling and tethering in the mouse cremaster model.
As a consequence, lung inflammation was reduced by
PXS-4728A during LPS stimulus, Klebsiella pneumo-
niae infection and CLP injury without impacting the
survival or susceptibility to infection, in addition to
improving outcomes of RV induced asthma. It is im-
portant to highlight that PXS-4728A diminished, but
did not abolish neutrophil influx to the lung and did
not change neutrophil counts in circulation, affording
a more beneficial approach to lung inflammation than
CXCR2 blockers, that have been shown to cause neu-
tropenia [19].
Figure 7 Inhibition of inflammation during CLP induces sepsis. Cecal ligation and puncture (CLP) was induced by ligating and perforating
the cecum. Cecal contents were expressed through the perforation. The cecum was placed back into the peritoneal cavity and the peritoneal
wall and skin incisions were then closed. 6 hours after surgery (A) total cells (B) and neutrophils were analysed in the peritoneal lavage. Inhibition
of inflammation by VAP-1/SSAO regulation was seen in the bronchoalveolar lavage, by a decrease in (C) total cell counts, (D) neutrophils and (E)
MPO. Treatment with PXS-4728A increased survival (F). N = 4-6 per group for the BALF, peritoneal lavage and MPO; N = 8/10 per group for
survival; **p < 0.01, ***p < 0.001 over sham.
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lial cells and has its enzymatically active domain outside
of the cell membrane. VAP-1 was originally discovered
to be an adhesion molecule [36], however cloning of the
antigen revealed that it also had semicarbazide-sensitive
amine oxidases (SSAO) activity [37]. Following these
findings, a number of in vitro studies demonstrated
that anti-VAP-1 mAbs as well as small molecule SSAO
inhibitors blocked leukocyte-endothelial cell interactions
[38,39], suggesting that both the adhesion and enzymatic
functions converge to a common process which regu-
lates leukocyte recruitment in vitro.
Deletion of VAP-1/SSAO increased leukocyte velocity,
thereby causing a decrease in leukocyte adhesion in the
mouse cremaster model, with similar results obtained
using an anti-mouse VAP-1 monoclonal antibody [34].
VAP-1/SSAO potentially acts as an important breaking
mechanism by reducing the velocity of rolling cells
allowing leukocytes to survey the endothelial cells for
signs that are required for subsequent adhesion [40]. Assuch, it was not surprising to find that the inhibition of
the enzymatic activity by PXS-4728A in the cremaster
model impaired the capacity of leukocytes to interact
with the vascular endothelium. However, for the first
time, direct pharmacological in vivo evidence is pre-
sented that VAP-1/SSAO inhibitor affects the rolling of
neutrophils and in fact acts as a breaking mechanism by
decreasing leukocyte-endothelial interaction.
The exact mechanisms of SSAO-leukocyte binding
were not elucidated here. However, a number of studies
have suggested that SSAO binds to arginine residues
present on the granulocyte Siglec-10 receptor [41].
Given that SSAO also binds to lysine residues [42,43], it
is possible that lysine residues present on the neutrophil
surface may facilitate the targeting of endothelial bound
SSAO, which could assist neutrophil tethering and roll-
ing on the endothelium. In fact, a number of neutrophil-
bound receptors have been found to be rich in lysine
residues such as CD44 as well CD68 [44-47], making
these receptors potential ligands for SSAO.
Figure 8 Inhibition of inflammation during viral induced asthma exacerbation. Allergic airways disease was established with house dust
mite (HDM) sensitization followed by HDM challenge. RV1b infection was superimposed on the allergic mice to induce an exacerbation and
results analysed 24 hours post infection. PXS-4728A reduced (A) total BALF neutrophils and (B) significantly reduced airways hyperreactivity to
methacholine challenge in ventilated mice as of 2.5 mg.ml−1. N = 8 per group for AHR and N = 4 per group for BALF; ***p < 0.001 over
HDM/vehicle/RV. AHR analysed by two-way ANOVA with Newman-Keuls Multiple Comparison Test.
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leukocyte behaviour has been predominantly analysed in the
systemic microcirculation, with ICAM-1 and various selec-
tins playing a key role on leukocyte adhesion and rolling
[5,11]. In the current study it was demonstrated that VAP-
1/SSAO is important in mediating adhesion and rolling in
the systemic circulation, as seen by inhibition of these steps
by PXS-4728A in the cremaster model. However, the adher-
ence between leukocytes and endothelial cells in injured
venules of the systemic circulation is somewhat different to
that of the pulmonary microcirculation with 90% of neutro-
phils originating from the capillaries [48], where adhesion
has not been implicated [14]. In order for leukocyte migra-
tion to occur in the lung capillaries, leukocytes must
undergo deformation [16] and the rolling is dependent on
ICAM-1 and E-selectin [14,16]. Although the current study
did not visualize the effects of VAP-1/SSAO on adhesion
and rolling in lung microcirculation it is clear that SSAO is
involved in those processes, as PXS-4728A inhibited neutro-
phil infiltration driven by different stimulus’ into the lung.
PXS-4728A reduced LPS-induced neutrophil invasion
into the lung. Consistent with these data it has been
shown that VAP-1/SSAO moderates leukocyte migration
and, inhibition of enzyme activity prolonged survival post
LPS-induced endotoxemia, whilst also reducing serum
levels of TNF-α and IL-6 [49]. Subsequent reports con-
firmed the role of VAP-1/SSAO during LPS stimulation in
the lung; with inflammatory cells in the BALF being
significantly higher in the VAP-1/SSAO transgenic than in
the non-transgenic mice, while blocking SSAO activity
reduced the number of neutrophils as well as a number of
related cytokines [24,25,50].PXS-4728A also reduced bacterial driven neutrophil
influx and lung inflammation. A number of studies have
demonstrated the importance of neutrophils for the clear-
ance of infections [5]. Indeed, patients who have severe
neutropenia are highly susceptible to infection [51,52].
Therefore, it was important to study the consequences of
VAP-1/SSAO inhibition on bacterial infection. The data
presented thus far in the literature are somewhat contra-
dictory; Koskinen et al. described that the antimicrobial
immune responses were affected by the deletion of VAP-1/
SSAO upon infection with either Staphylococcus aureus
(gram positive bacteria) or coxsackie B4 virus. However,
when the function of VAP-1 was neutralized using small
molecule enzyme inhibitors and anti-VAP-1 Abs, rather
than by gene deletion, no significant impairment in anti-
microbial response against these same infections was re-
ported [53]. The latter had also been observed by Stolen
et al., in which the mortality of VAP-1/SSAO deficient ani-
mals infected with the gram-negative bacteria Yersinia
enterocolitica was not higher than that of similarly infected
WT littermates [34]. Our results are in agreement with the
concept that small molecule enzyme inhibitors do not
negatively impact on the survival of animals upon infection
or sepsis but diminish neutrophil load in the BALF. VAP-
1/SSAO inhibition led to an increase in bacterial load dur-
ing Klebsiella pneumoniae infection that was insufficient to
impart on survival of the animals. These studies, therefore,
show that treatment with a VAP-1/SSAO inhibitor, is
accompanied by neutrophil recruitment at a sufficient level
to effectively combat infection, yet in low enough numbers
to diminish lung injury. Consistent with these findings,
VAP-1/SSAO inhibition significantly dampened the lung
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with PXS-4728A demonstrated an improved survival over
untreated animals, this did not reach significance, which
might be attributed to the low number of animals in the
model.
It is noteworthy that the properties of PXS-4728A are
specific to neutrophil extravasation and not an off-target
effect. When animals were infected with Klebsiella pneu-
moniae they had no impairment in survival, suggesting no
issues with neutrophil phagocytosis. At the 6 hour time
point in the CLP model, SSAO activity was completely
abolished (given the PK/PD profile of PXS-4728A). At this
stage MPO activity returned to baseline levels, which was
concomitant with a significant reduction in neutrophils.
Thus indicating that inhibition of myeloperoxidase was a
direct effect of the reduction in neutrophils. In addition,
there was no evidence that the compound could have dir-
ect effects on bacteria, as no direct homolog with AOC3
has yet been described for bacterial enzymes. Although
Klebsiella pneumoniae contains a related TPQ, given the
high specificity of PXS-4728A for AOC3 over the AOC1
and AOC2 gene products, it can be presumed that a direct
effect of PXS-4728A on the bacteria is highly unlikely.
The beneficial effects of inhibiting VAP-1/SSAO in
bacterial inflammation models were extended to another
clinically relevant setting. Asthma exacerbations are most
commonly triggered by infection with viruses detected in
85% of asthmatic hospitalizations and 2/3rds of these are
Rhinovirus (RV) [54,55]. Neutrophils are the key cell type
in the immune response to RV infection and have been
strongly implicated asthma pathogenesis with neutrophil
degranulation associated with asthmatic severity [56] and
neutrophilic TNF-α required for the induction of AHR in
mouse models [57]. Azithromycin was used as a compara-
tor, as macrolide therapy is showing promise in the clinic,
with Brusselle et al. reporting that azithromycin treatment
reduced exacerbation rates in patients with severe neutro-
philic asthma (although significance was lost when all
patients were analysed together) [58]. PXS-4728A reduced
cellular infiltrate and significantly reduced airways hyperre-
activity (AHR), an effect that was comparable to that of the
macrolide azithromycin. Therefore, the anti-inflammatory
properties of PXS-4728A can dampen Rhinovirus- induced
asthma exacerbation.
It is important to point out that data from a single experi-
mental mouse model needs to be carefully interpreted and
its limitations appreciated. The use of dexamethasone as a
comparator is a classic example of this limitation. It is well
appreciated that in the clinical setting neutrophilic inflam-
mation is less responsive to dexamethasone treatment,
however, in acute rodent models it has been shown that
dexamethasone is very effective [24,28]. In the current study
dexamethasone was utilized as a broad anti-inflammatory
agent as it is currently one of the gold standards for acuteinflammation. By using various models of lung inflammation
in different strains as well as the use of relevant compara-
tors, dexamethasone and azithromycin, the limitation of sin-
gle models should have been overcome and the data should
enable the development of PXS-4728A for respiratory
diseases.
Conclusions
Taken together, these results show the anti-inflammatory
effects of inhibiting VAP-1/SSAO enzymatic function and
highlight the potential of PXS-4728A as a novel thera-
peutic tool in diseases that are characterized by a neutro-
philic pattern of inflammation, including acute lung injury,
chronic obstructive pulmonary disease, cystic fibrosis, and
bronchiolitis obliterans syndrome.
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